dr. H.H. (Herma) Fidder

dr. H.H. (Herma) Fidder

Assistant Professor - medical
  • Gastroenterology and Hepatology

Research Programs

Research Output (125)

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

D'Haens Geert, Dubinsky Marla, Kobayashi Taku, Irving Peter M, Howaldt Stefanie, Pokrotnieks Juris, Krueger Kathryn, Laskowski Janelle, Li Xingyuan, Lissoos Trevor, Milata Joe, Morris Nathan, Arora Vipin, Milch Catherine, Sandborn William, Sands Bruce E, , Fidder H 29 Jun 2023, In: The New England journal of medicine. 388 , p. 2444-2455 12 p.

Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis

van de Meeberg Maartje M, Verheij Elwin R, Fidder Herma H, Bouma Gerd, Huitema Alwin D R, Oldenburg Bas 22 Feb 2023, In: Therapeutic drug monitoring. 45 , p. 668-675 8 p.

Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease:A Prospective Multicentre Registry Study

Simsek Melek, Schepers Femke, Kaplan Sigal, Van Asseldonk Dirk, Van Boeckel Petra, Boekema Paul, Dijkstra Gerard, Fidder Herma, Gisbertz Ingrid, Hoentjen Frank, Jharap Bindia, Kubben Frank, De Leest Marleen, Meijssen Maarten, Petrak Ana, Van De Poel Else, Russel Maurice, Van Bodegraven Adriaan A., Mulder Chris J.J., De Boer Nanne 25 Jan 2023, In: Journal of Crohn's & Colitis. 17 , p. 933-942 10 p.

Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn's disease:a cross-sectional study

van de Meeberg M. M., Seinen M. L., Fidder H. H., Lin M., Oldenburg B., de Boer N. K., Bouma G., de Jonge R., Bulatović Ćalasan M., 30 Jul 2022, In: BMC Gastroenterology. 22

Authors' reply - Immunomodulator Withdrawal From Anti-TNF Therapy Needs A Careful Patient Selection -

Mahmoud Remi, Schultheiss Johannes P D, Fidder Herma H, Oldenburg Bas 25 Apr 2022, In: Clinical Gastroenterology and Hepatology. 21 , p. 558-559 2 p.

Letter:loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease—authors' reply

Mahmoud Remi, Schultheiss Johannes P.D., Fidder Herma H., Oldenburg Bas Feb 2022, In: Alimentary Pharmacology and Therapeutics. 55 , p. 499-500 2 p.

Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease

Mahmoud Remi, Schultheiss Hans-Paul, Louwers Jonas, van der Kaaij M T, van Hellemondt B P, Mahmmod N, van Boeckel P G, Jharap B, Fidder Herma, Oldenburg Bas 28 Jan 2022, In: Clinical Gastroenterology and Hepatology. 20 , p. 2577-2587.e6

A Systematic Review with Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease:What Can We Learn from Randomized and Nonrandomized Studies?

Doeve Benthe H., Van De Meeberg Maartje M., Van Schaik Fiona D.M., Fidder Herma H. 1 Oct 2021, In: Journal of Clinical Gastroenterology. 55 , p. 798-809 12 p.

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands

De Bock Ellen, Filipe Mando D., Meij Vincent, Oldenburg Bas, Van Schaik Fiona D.M., Bastian Okan W., Fidder Herma F., Vriens Menno R., Richir Milan C. 2 Jul 2021, In: BMJ Open Gastroenterology. 8

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not